Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

BMJ (Online)

Volumn 343, Issue 7834, 2011, Pages 1136-

  Hemmingsen, Bianca ^a   Lund, Søren S ^b   Gluud, Christian ^a   Vaag, Allan ^a   Almdal, Thomas ^b   Hemmingsen, Christina ^a   Wetterslev, Jørn ^a  

^a Rigshospitalet   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPARATIVE STUDY; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEQUENTIAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 82755165018     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d6898     Document Type: Article

References (122)

1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. (Pubitemid 30609442)
2. Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol 2006;17:637-43. (Pubitemid 44729956)
3. Selvin E, Ning Y, Steffes MW, Bash LD, Klein R, Wong TYAB, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011;60:298-305.
4. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
5. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. (Pubitemid 351831357)
6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
7. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus-a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
9. Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010;53:2079-85.
10. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(suppl 1):S11-61.
11. International Diabetes Federation. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579-93.
12. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30.
13. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Wetterslev J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;4:CD008143.
14. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;6:CD008143.
15. Higgins JPT, Green S. Cochrane handbook for systematic reviews of intervention 5.0.0. Cochrane Collaboration, 2008 (available from cochrane-handbook.org).
16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91. (Pubitemid 351214285)
17. Guo LX, Pan Q, Wang XX, Li H, Zhang LN, Chi JM, et al. Effect of short term intensive multitherapy on carotid intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus. Chinese Med J 2008;121:687-90.
18. Yang JM, Guo XH, Yu X. Long-term intensive glycemic and lipid control ameliorates the carotid intima medial thickness in type 2 diabetes mellitus. Journal of Peking University Health Sciences 2007;39:649-52.
19. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-61. (Pubitemid 40516876)
20. Melidonis A, Stefanidis A, Tournis S, Manoussakis S, Handanis S, Zairis M, et al. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol 2000;23:160-4. (Pubitemid 30127452)
21. Stefanidis A, Melidonis A, Tournis S, Zairis M, Handanis S, Beldekos D, et al. Effect of intravenous insulin administration on left ventricular performance during non-ST-elevation acute coronary events in patients with diabetes mellitus. Am J Cardiol 2003;91:1237-40. (Pubitemid 36561390)
22. Review Manager (RevMan) [computer program]: version 5.0.25. Cochrane Collaboration,2011.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
24. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987;6:341-50.
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2011;21:1539-58.
26. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis-a simulation study. PLos One 2011;6:e25491.
27. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64-75.
28. Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. Stat Med 2011;30:903-21.
29. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 2009;30:86.
30. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008;61:763-9.
31. Barnett AH. Treatment intensification in patients with type 2 diabetes. Diabetes Obes Metab 2008;10(suppl 1):iii.
32. Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, et al. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. J Nephrol 2001;14:461-71. (Pubitemid 34168280)
33. Clark R, English M, McNeill G, Newton R. Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. BMJ 1985;291:303-5. (Pubitemid 15045109)
34. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004;43:8-14. (Pubitemid 38045906)
35. Eastman RC, Eastman RC. Is intensive glycemic control worth the expense? Cleve Clin J Med 1997;64:410-3. (Pubitemid 127470837)
36. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004;34:205-9. (Pubitemid 38406635)
37. Evans RJ, Lane J, Holman RR, Turner RC. Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes. Diabetes Care 1982;5:433-7. (Pubitemid 12093564)
38. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thoracic Surg 1999;67:352-60.
39. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:65-71.
40. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-32. (Pubitemid 38579760)
41. Leibowitz G, Raizman E, Brezis M, Glaser B, Raz I, Shapira O. Effects of moderate intensity glycemic control after cardiac surgery. Ann Thorac Surg 2010;90:1825-32.
42. Barbosa J, Connett J, Fryd D, Sutherland D, Rao V, Anderson R, et al. The Minnesota diabetes complications clinical trial: the first three years. Acta Diabetologica Latina 1983;20:165-71. (Pubitemid 13007500)
43. Blaha J, Kopecky P, Matias M, Hovorka R, Kunstyr J, Kotulak T, et al. Comparison of three protocols for tight glycemic control in cardiac surgery patients. Diabetes Care 2009;32:757-61.
44. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004;109:1497-502. (Pubitemid 38420177)
45. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 1996;17:1337-44. (Pubitemid 26306661)
46. Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2010;33:177-83.
47. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009;120:2529-40.
48. Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care 2009;32:977-82.
49. Cleveringa FGW, Minkman MH, Gorter KJ, Van den Donk M, Rutten GEHM. Diabetes care protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care. Diabet Med 2010;27:442-50.
50. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)
51. Du JL, Liu JF, Men LL, Yao JJ, Sun LP, Sun GH, et al. Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus. Chinese Med J 2009;122:2560-6.
52. Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. Diabet Med 2010;27:175-80.
53. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999;22:960-4. (Pubitemid 29241052)
54. Johansen OE, Gullestad L, Blaasaas KG, Orvik E, Birkeland KI. Effects of structured hospital-based care compared with standard care for type 2 diabetes - the Asker and Baerum Cardiovascular Diabetes Study, a randomized trial. Diabet Med 2007;24:1019-27. (Pubitemid 47301639)
55. Joss N. Intensive medical management in type 2 diabetes and nephropathy: renal consequences [abstract no: SU-P0860]. J Am Soc Nephrol 2002;13:646A.
56. Menard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ 2005;173:1457-66.
57. Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001;323:970-5. (Pubitemid 33016046)
58. Piatt GA, Anderson RM, Brooks MM, Songer T, Siminerio LM, Korytkowski MM, et al. 3-year follow-up of clinical and behavioral improvements following a multifaceted diabetes care intervention: results of a randomized controlled trial. Diabetes Educ 2010;36:301-9.
59. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-6.
60. Shi Q, Ostwald SK, Wang S. Improving glycaemic control self-efficacy and glycaemic control behaviour in Chinese patients with type 2 diabetes mellitus: randomised controlled trial. J Clin Nurs 2010;19:398-404.
61. Van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract 2009;26:428-36.
62. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22. (Pubitemid 29087981)
63. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93. (Pubitemid 36159355)
64. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31:1510-5.
65. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008;29:166-76.
66. Stefanidis A, Melidonis A, Tournis S, Zairis M, Handanis S, Olympios C, et al. Intensive insulin treatment reduces transient ischaemic episodes during acute coronary events in diabetic patients. Acta Cardiol 2002;57:357-64.
67. Action to Control Cardiovascular Risk in Diabetes Study. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Protocol. 2009. www.accordtrial.org/public/documents/ Protocol%20All%20Chapters.pdf.
68. Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:80i-9i.
69. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
70. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i.
71. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.
72. Cushman WC, Evans GW, Byington RP, Goff DCJ, Grimm RHJ, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
73. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
74. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-30.
75. Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009;52:2027-36.
76. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009;32:2068-74.
77. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-8.
78. ADVANCE Collaborative Group. ADVANCE. 2011. www.advance-trial.com.
79. Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:5491-7. (Pubitemid 33070280)
80. Bagg W. Cardiac and endothelial function is unaffected by short-term intensive glycaemic control in patients with type-2 diabetes mellitus [abstract]. Int Med J 2001;31:A1.
81. Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab 2001;3:410-6. (Pubitemid 34030859)
82. Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N, Braatvedt GD, et al. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J 2001;31:322-8. (Pubitemid 34225185)
83. Becker A, van der Does FEE, van Hinsbergh VWM, Heine RJ, Bouter LM, Stehouwer CDA. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, von Willebrand factor and (pro)insulin. Neth J Med 2003;61:129-36. (Pubitemid 39089384)
84. Van der Does FE, de Neeling JN, Snoek FJ, Grootenhuis PA, Kostense PJ, Bouter LM, et al. Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes: effects on well-being at 1 year. Diabetes Care 1998;21:2085-93. (Pubitemid 28549155)
85. Lapina YV, Filatov DN, Mareev VY, Yu O, Bolotina MG, Shestakova MV, et al. Effect of strict glycemic control on clinical state and course of the disease in patients with chronic heart failure and type II diabetes mellitus: results of the REMBO (Rational Effective Multicomponent therapy in the struggle against diaBetes mellitus in patients with cOngestve heart failure) Study. Kardiologiya 2008;48:17-27.
86. Lu WH, Shi BY, Zhang XT, Wei DG, Liu WD, Duan PZ. Significance of intensive glycemic control on early diabetic nephropathy patients with microalbuminuria. Academic Journal of Xi'an Jiaotong University 2010;22:135-8.
87. Service FJ, Daube JR, O'Brien PC, Zimmerman BR, Swanson CJ, Brennan MD, et al. Effect of blood glucose control on peripheral nerve function in diabetic patients. Mayo Clin Proc 1983;58:283-9. (Pubitemid 13060417)
88. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978;240:37-42. (Pubitemid 8395565)
89. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods and baseline results. Diabetes 1970;19:747-72.
90. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. Diabetes 1970;19:789-830.
91. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VIII. Evaluation of insulin therapy: final report. Diabetes 1982;31(suppl 5):1-81.
92. Hage C, Norhammar A, Grip L, Malmberg K, Sarkar N, Svane B, et al. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. Diab Vasc Dis Res 2009;6:71-9.
93. Yngen M, Norhammar A, Hjemdahl P, Wallén NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res 2006;3:52-6. (Pubitemid 43877254)
94. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43. (Pubitemid 126497295)
95. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(suppl 2):B21-9. (Pubitemid 30185774)
96. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000;48:201-10. (Pubitemid 30232841)
97. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
98. Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS 51). Diabetologia 2001;44:298-304. (Pubitemid 32234454)
99. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77. (Pubitemid 40767979)
100. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
101. UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22:1125-36.
102. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study (UKPDS) VIII: study design, progress and performance. Diabetologia 1991;34:877-90.
103. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med 1997;157:181-8.
104. Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Diabetes Care 2000;23:1478-85.
105. Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, et al. Evaluations of retinopathy in the VA cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Diabetes Care 1996;19:1375-81. (Pubitemid 26418618)
106. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, et al. Glycemic control and complications in type II diabetes: design of a feasibility trial. Diabetes Care 1992;15:1560-71.
107. Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C, et al. Health-related quality of life in the VA feasibility study on glycemic control and complications in type 2 diabetes mellitus. J Diabetes Complications 2005;19:207-11. (Pubitemid 40910201)
108. Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998;21:574-9. (Pubitemid 28172937)
109. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care 1995;18:1113-23.
110. Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2 Veterans Affairs diabetes trial. J Diabetes Complications 2003;17:314-22. (Pubitemid 37315940)
111. Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab 2009;11:150-6.
112. Fermi Paradox. www.crystalinks.com/fermiparadox.html.
113. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169.
114. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98.
115. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009;19:604-12.
116. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72.
117. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009;151:394-403.
118. Wu H, Xu MJ, Zou DJ, Han QJ, Hu X. Intensive glycemic control and macrovascular events in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Chinese Med J 2010;123:2908-13.
119. Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res 2010;7:119-30.
120. Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. Ann Med 2010;42:305-15.
121. Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutr Metab Cardiovasc Dis 2009;19:596-603.
122. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DCJ, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28.